Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Dementia and Neurocognitive Disorders|February 9, 2026
Erratum: Nationwide Survey on the Awareness of Mild Cognitive ImpairmentHyuk Sung Kwon, Kee Hyung Park, Jin San Lee, et al.Journal of Neurology|March 11, 2026
Saccadic variability in patients with Parkinson's diseaseKyoungwon Baik, Seoyeon Byun, Seoui Kwag, et al.Biosensors & Bioelectronics|November 22, 2025
Machine learning-assisted high-performance immunoSERS platform using silk fibroin as a natural etching mask for early diagnosis of Alzheimer's diseaseSoo Hyun Lee, Soohyun Kim, Jong Uk Lee, et al.Journal of Medicinal Food|June 30, 2025
Efficacy and Safety of MT104, A Dietary Supplement Based on Cuscuta Seeds and Heat-Killed Probiotics, on Cognitive Function in Patients with Mild Cognitive Impairment: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical TrialBo-Hyung Kim, Minji Kwon, Sung-Vin Yim, et al.Journal of Clinical Neurology (Seoul, Korea)|June 29, 2021
Impact of an Education Program for Caregivers of Patients with Alzheimer's Disease on Treatment Discontinuation and Compliance in KoreaHee Jin Kim, Yong S Shim, Kee Hyung Park, et al.Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society|April 23, 2024
Sympathetic dysfunction as an early indicator of autonomic involvement in Parkinson's diseaseJin-Woo Park, Luis E Okamoto, Sung-Hwan Kim, et al.Dementia and Neurocognitive Disorders|August 7, 2023
Effects of GV1001 on Language Dysfunction in Patients With Moderate-to-Severe Alzheimer's Disease: Post Hoc Analysis of Severe Impairment Battery SubscalesHyuk Sung Kwon, Seong-Ho Koh, Seong Hye Choi, et al.Alzheimer'S Research & Therapy|March 27, 2021
Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trialSeong-Ho Koh, Hyuk Sung Kwon, Seong Hye Choi, et al.Alzheimer'S Research & Therapy|July 15, 2020
CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer's disease as an indicator of tau phosphorylationKyu Hwan Shim, Min Ju Kang, Jee Won Suh, et al.Dementia and Neurocognitive Disorders|November 8, 2024
Lecanemab: Appropriate Use Recommendations by Korean Dementia AssociationKee Hyung Park, Geon Ha Kim, Chi-Hun Kim, et al.Pageof 5